A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)

ClinicalTrials.gov ID: NCT01235520

Public ClinicalTrials.gov record NCT01235520. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase III, Multi-center, Randomized, 12-week, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia Treated With Antipsychotics Followed by a 40-week Double-blind, Parallel-group, Placebo-controlled Treatment Period.

Study identification

NCT ID: NCT01235520
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Hoffmann-La Roche; Industry
Enrollment: 595 participants

Conditions and interventions

Conditions

Schizophrenia

Interventions

Placebo Drug
RO4917838 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Dec 31, 2010
Primary completion: Jun 30, 2014
Completion: Jun 30, 2014
Last update posted: Jun 1, 2015

2011 – 2014

United States locations

U.S. sites: 30
U.S. states: 16
U.S. cities: 27

Facility	City	State	ZIP	Site status
Not listed	Little Rock	Arkansas	72201	—
Not listed	Little Rock	Arkansas	72211	—
Not listed	Buena Park	California	90620	—
Not listed	Cerritos	California	90703	—
Not listed	Downey	California	90241	—
Not listed	La Palma	California	90623	—
Not listed	Pasadena	California	91106	—
Not listed	Pico Rivera	California	90660	—
Not listed	Miami	Florida	33126	—
Not listed	Miami	Florida	33136	—
Not listed	Marietta	Georgia	30060	—
Not listed	Oak Brook	Illinois	60523	—
Not listed	Iowa City	Iowa	52242	—
Not listed	Glen Burnie	Maryland	21061	—
Not listed	Las Vegas	Nevada	89102	—
Not listed	Toms River	New Jersey	08775	—
Not listed	Willingboro	New Jersey	08046	—
Not listed	Albuquerque	New Mexico	87108	—
Not listed	Brooklyn	New York	11201	—
Not listed	Fresh Meadows	New York	11366	—
Not listed	New York	New York	10035	—
Not listed	Raleigh	North Carolina	27603	—
Not listed	Cincinnati	Ohio	45206	—
Not listed	Philadelphia	Pennsylvania	19131	—
Not listed	Scranton	Pennsylvania	18503	—
Not listed	Bellaire	Texas	77401	—
Not listed	Dallas	Texas	75231	—
Not listed	Dallas	Texas	75243	—
Not listed	The Woodlands	Texas	77381	—
Not listed	Kirkland	Washington	98033	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 91 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01235520, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 1, 2015 · Synced Jul 23, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01235520 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →